



Provincial Health Services Authority

Information on this form is a guide only. User will be solely responsible for verifying its currency and accuracy with the corresponding BC Cancer treatment protocols located at www.bccancer.bc.ca and according to acceptable standards of care

PROTOCOL CODE: UMY0UF (teclistamab)
Cycle 2+

A BC Cancer "Compassionate Access Program" request form must be completed and approved prior to treatment.

DOCTOR'S ORDERS		Ht _____ cm	Wt _____ kg	BSA _____ m ²
REMINDER: Please ensure drug allergies and previous bleomycin are documented on the Allergy & Alert Form				
DATE:	To be given:	Cycle #:		
Date of Previous Cycle: _____				
<input type="checkbox"/> Delay treatment _____ week(s) <input type="checkbox"/> CBC & Diff, platelets day of treatment				
May proceed with doses as written if within 48 hours ANC greater than or equal to 0.5 x 10⁹/L, platelets greater than or equal to 25 x 10⁹/L (without bleeding), and no signs or symptoms of CRS or ICANS.				
Dose modification for: <input type="checkbox"/> Other Toxicity: _____ Proceed with treatment based on blood work from _____				
<ul style="list-style-type: none"> Per physician's clinical judgement, physician to ensure prophylaxis with antiviral/antifungal/antibacterial 				
PREMEDICATIONS: Patient to take own supply. RN/Pharmacist to confirm _____.				
<input type="checkbox"/> prochlorperazine 10 mg PO or <input type="checkbox"/> metoclopramide 10 mg PO prior to each dose of teclistamab				
If required (if CRS with prior dose, or when resuming treatment after treatment interruption*)				
<input type="checkbox"/> dexamethasone 20 mg <input type="checkbox"/> PO or <input type="checkbox"/> IV (select one) 60 minutes prior to each dose of teclistamab <input type="checkbox"/> acetaminophen 650 mg to 975 mg PO prior to each dose of teclistamab				
Select one of the following:				
<input type="checkbox"/> loratadine 20 mg PO prior to each dose of teclistamab OR <input type="checkbox"/> diphenhydrAMINE 50 mg <input type="checkbox"/> PO or <input type="checkbox"/> IV (select one) prior to each dose of teclistamab				
* Refer to Protocol for suggested indications for premedications				
<input type="checkbox"/> Other: _____				
Have Hypersensitivity Reaction Tray & Protocol Available				
TREATMENT:				
teclistamab 1.5 mg/kg x _____ kg = _____mg subcutaneous injection on Days 1, 8, 15, and 22 Administer doses greater than 2 mL as two syringes at two separate sites.				
Observe for 30 minutes post-injection. Vital signs prior to treatment and at 30 minutes post-injection.				
DOCTOR'S SIGNATURE:			SIGNATURE:	
			UC:	



Provincial Health Services Authority

Information on this form is a guide only. User will be solely responsible for verifying its currency and accuracy with the corresponding BC Cancer treatment protocols located at www.bccancer.bc.ca and according to acceptable standards of care

PROTOCOL CODE: UMY0UF (teclistamab)
Cycle 2+

DATE:

RETURN APPOINTMENT ORDERS

Return in four weeks for Doctor and Cycle _____. Book treatment on Days 1, 8, and 15.

CBC & Diff, platelets, creatinine, urea, sodium, potassium, total bilirubin, ALT, alkaline phosphatase, calcium, albumin, LDH, random glucose, serum protein electrophoresis and serum free light chain levels every 4 weeks

- Urine protein electrophoresis every 4 weeks
- Immunoglobulin panel (IgA, IgG, IgM) every 4 weeks
- Beta-2 microglobulin every 4 weeks
- CBC & Diff, platelets Days 8, 15, 22
- Creatinine, sodium, potassium Days 8, 15, 22
- Total bilirubin, ALT, alkaline phosphatase Days 8, 15, 22
- Random glucose Days 8, 15, 22
- Calcium, albumin Days 8, 15, 22
- Phosphate
- Magnesium
- MUGA scan or Echocardiogram
- ECG
- Other tests:
- Consults:
- See general orders sheet for additional requests

DOCTOR'S SIGNATURE:

SIGNATURE:

UC: